2002
DOI: 10.1385/mo:19:1:59
|View full text |Cite
|
Sign up to set email alerts
|

In Vivo Use of All-Trans Retinoic Acid Prior to Induction Chemotherapy Improves Complete Remission Rate and Increases Rhodamine 123 Uptake in Patients with De Novo Acute Myeloid Leukemia

Abstract: All-trans retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia. Because ATRA has effects (increase in apoptosis, suppression of bcl-2), it has also been used for the treatment of other French-American-British (FAB) subtypes of acute myelogenous leukemia (AML). To find out the in vivo and in vitro effects of ATRA in AML, we analyzed 37 patients with de novo AML. Twenty-seven patients received ATRA before remission-induction (RI) treatment (ATRA group). Results were compared to a control… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2002
2002
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 34 publications
0
2
0
Order By: Relevance
“…Accordingly, the survivin mRNA expression of APL cells is lower. The researcher has proved that ATRA treatment prior to chemotherapy may improve the CR rate in patients with de novo AML, which seems to be related to its beneficial effect on multidrug resistance [6]. …”
Section: Discussionmentioning
confidence: 99%
“…Accordingly, the survivin mRNA expression of APL cells is lower. The researcher has proved that ATRA treatment prior to chemotherapy may improve the CR rate in patients with de novo AML, which seems to be related to its beneficial effect on multidrug resistance [6]. …”
Section: Discussionmentioning
confidence: 99%
“…Some early clinical trials have been conducted, but resulting conclusions were confusing. Some trials did not show benefits of combination therapy for patients [103,104], while others did [105]. Therefore a search for more specific differentiation agents for non-APL AML is underway and will be discussed below.…”
Section: New Treatments For Acute Promyelocytic Leukemia As Examples mentioning
confidence: 99%